Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 0.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.17 | - |
NAV | ₹15.90 | - |
Fund Started | 14 Sep 2023 | - |
Fund Size | ₹1382.60 Cr | - |
Exit Load | Exit load of 1%, if redeemed within 30 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 50.48% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
3 Year
5 Year
Equity | 99.23% | - |
Cash | 0.77% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 14.02% |
Cipla Ltd. | 8.17% |
Divi's Laboratories Ltd. | 7.91% |
Lupin Ltd. | 6.25% |
Ipca Laboratories Ltd. | 4.08% |
Gland Pharma Ltd. | 4.00% |
Aurobindo Pharma Ltd. | 3.44% |
Piramal Pharma Ltd. | 3.41% |
Dr. Reddy's Laboratories Ltd. | 3.32% |
Eris Lifesciences Ltd. | 3.27% |
Name | Dhruv Muchhal | - |
Start Date | 14 Sep 2023 | - |
Name
Start Date
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | - |
Launch Date | 14 Sep 2023 | - |
Description
Launch Date